Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2024-01-30 , DOI: 10.1080/14737167.2023.2295474
Elaine Hsuen Lim ₁ , Andrew Lim ₂ , Jasmeet Singh Khara ₃ , John Cheong ₄ , Jek Fong ₄ , Sivabalan Sivanesan ₃ , Matt Griffiths ₅ , Emma New ₆ , Soo Chin Lee ₇

Affiliation

The Asian PEONY trial showed that add-on pertuzumab to trastuzumab and chemotherapy significantly improved pathological complete response in the neoadjuvant treatment of patients with human epiderm...

中文翻译：